Prothena Corporation plc (PRTA) Stock
Key stats
- Market cap
- $448.28M
- Price / Earnings ratio
- -18.3x
- EPS (TTM)
- -$0.47
- Volume
- Loading
- 52-week high
- $11.80
- 52-week low
- $7.73
Source: third-party data provider, as of November 13, 2026
Compare with PRTA
Recent news
Prothena to Report Third Quarter 2026 Financial Results on November 5
Prothena to Report Third Quarter 2026 Financial Results on November 5
PRTA
Prothena's Partnership Strategy: Growth Driver or Limitation?
Prothena's Partnership Strategy: Growth Driver or Limitation?
PRTA
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
PRTA
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
PRTANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 53.74
- MACD 12/26/9
- -0.02
- EMA 9 of MACD
- -0.05
- MACD histogram
- 0.03
- SMA 50
- $8.60
- Price above SMA 50
- EMA 50
- $8.58
- Price above EMA 50
- SMA 200
- $9.18
- Price below SMA 200
- EMA 200
- $9.14
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.38 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Prothena to Report Third Quarter 2026 Financial Results on November 5
Prothena to Report Third Quarter 2026 Financial Results on November 5
PRTAProthena's Partnership Strategy: Growth Driver or Limitation?
Prothena's Partnership Strategy: Growth Driver or Limitation?
PRTACRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
PRTA4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
PRTA
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PRTA
KMDA or PRTA: Which Is the Better Value Stock Right Now?
KMDA or PRTA: Which Is the Better Value Stock Right Now?
PRTA
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
PRTA
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
PRTA
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
PRTA
Prothena to Report Second Quarter 2026 Financial Results on August 6
Prothena to Report Second Quarter 2026 Financial Results on August 6
PRTANews tone: automated (AI) classification of the article's content, not a price prediction.
About Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gene G. Kinney Ph.D. | President, CEO & Director | 1969 |
| Mr. Tran B. Nguyen M.B.A. | Chief Financial Officer | 1974 |
| Mr. Brandon S. Smith | Chief Operating Officer | 1975 |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer | 1973 |
| Dr. Chad H. Swanson Ph.D. | Chief Development Officer | — |
| Ms. Karin L. Walker CPA | Chief Accounting Officer & Controller | 1963 |
| Mr. Mark C. Johnson C.F.A. | Vice President of Investor Relations | — |
| Mr. Michael J. Isaacs | General Counsel & Corporate Secretary | — |
| Phillip Dolan | Sr. Director & Head of Exploratory Research | — |
| Ms. Annie Evans Kingston | Chief Strategy Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.74
- MACD 12/26/9
- -0.02
- EMA 9 of MACD
- -0.05
- MACD histogram
- 0.03
- SMA 50
- $8.60
- Price above SMA 50
- EMA 50
- $8.58
- Price above EMA 50
- SMA 200
- $9.18
- Price below SMA 200
- EMA 200
- $9.14
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.3 | +5.9 | ||||||||||
| 2022 | -30.8 | -0.2 | +9.5 | -25.3 | -11.1 | +2.4 | +11.4 | -7.2 | +120.2 | -0.6 | -1.5 | -1.1 |
| 2023 | +5.7 | +3.9 | -13.4 | +8.0 | +23.5 | +2.8 | +0.2 | -23.5 | -12.5 | -21.7 | -11.2 | +4.2 |
| 2024 | -26.3 | +0.8 | -13.2 | -22.2 | -2.8 | -6.9 | +13.7 | -0.2 | -21.2 | +2.1 | -2.6 | -7.7 |
| 2025 | +4.1 | +17.6 | -13.6 | -21.6 | -47.4 | +30.3 | +9.7 | +20.4 | +18.0 | +8.4 | +2.0 | -7.0 |
| 2026 | -4.2 | -2.7 | +3.4 | +10.3 | -4.3 | +2.1 | -15.2 | +12.2 | -12.8 | -0.8 | +5.3 |
